CE19 - Technologies pour la santé

Polydepsipeptide based microparticles as drug delivery systems in ophtalmic conditions – PDP-Act

Submission summary

Ocular drug delivery systems (DDS) to target the retina evolve rapidly, however effective pharmaceutical treatments to directly block optic nerve degeneration in glaucoma are not available. Intravitreal injection of API-loaded microparticles represent a promising strategy to improve long-term efficacy while solving acknowledged compliance issues. This project aims to develop a new DDS based on injectable and resorbable polydepsipeptide (PDP) microparticles for intravitreal sustained release of a neuroprotective drug developed by MT-act. Using our approach, key parameters including the starting amino-acid and size particle of the PDPs can advantageously be optimized to modulate loading and fine-tune delivery kinetics. The formulation will produce an injectable DDS with an adapted drug loading rate and a sustained bioactivity profile in the vitreal humor to engage therapeutic target in the retina cells. Synthesis scale-up of the most promising materials will be carried out by the environmentally compliant mechanochemistry and evaluated for cytotoxicity and drug efficiency in preclinical models.

Project coordination

Olivia GIANI (Institut Charles Gerhardt Montpellier)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

ICGM Institut Charles Gerhardt Montpellier
IBMM Institut des Biomolécules Max Mousseron
MT-ACT MT-ACT

Help of the ANR 606,373 euros
Beginning and duration of the scientific project: May 2023 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter